- Home
- SHLS vs AUPH Comparison
SHLS vs AUPH Comparison
Compare SHLS & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHLS | AUPH |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | SHLS | AUPH |
|---|---|---|
| Price | $9.04 | $16.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 4 |
| Target Price | $9.33 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 4.1M | 1.3M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.19 | ★ 0.55 |
| Revenue | ★ $433,993,000.00 | $265,808,000.00 |
| Revenue This Year | $20.62 | $21.76 |
| Revenue Next Year | $18.88 | $16.45 |
| P/E Ratio | $47.92 | ★ $29.47 |
| Revenue Growth | 2.68 | ★ 20.62 |
| 52 Week Low | $2.71 | $6.55 |
| 52 Week High | $11.36 | $16.54 |
Technical Indicators
Market Signals| Indicator | SHLS | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 56.11 | 62.80 |
| Support Level | $8.90 | $16.00 |
| Resistance Level | $9.59 | $16.54 |
| Average True Range (ATR) | 0.62 | 0.44 |
| MACD | 0.12 | -0.03 |
| Stochastic Oscillator | 67.47 | 80.77 |
Price Performance
Historical ComparisonAbout SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.